First Trust Advisors LP purchased a new stake in Smith & Nephew plc (NYSE:SNN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 10,093 shares of the medical equipment provider's stock, valued at approximately $248,000.
A number of other institutional investors have also made changes to their positions in the business. Principal Securities Inc. grew its stake in shares of Smith & Nephew by 87.6% in the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock valued at $36,000 after acquiring an additional 691 shares in the last quarter. R Squared Ltd bought a new stake in shares of Smith & Nephew during the fourth quarter worth $41,000. National Bank of Canada FI boosted its holdings in shares of Smith & Nephew by 36.5% during the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock valued at $41,000 after acquiring an additional 446 shares in the last quarter. Hara Capital LLC raised its position in Smith & Nephew by 391.4% in the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock valued at $60,000 after purchasing an additional 1,957 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Smith & Nephew by 31.8% during the fourth quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider's stock valued at $73,000 after purchasing an additional 718 shares in the last quarter. Institutional investors own 25.64% of the company's stock.
Analyst Ratings Changes
Several brokerages have issued reports on SNN. Canaccord Genuity Group boosted their price target on Smith & Nephew from $27.00 to $28.00 and gave the company a "hold" rating in a research note on Thursday, May 1st. Hsbc Global Res downgraded Smith & Nephew from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. HSBC downgraded Smith & Nephew from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. StockNews.com upgraded shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 26th. Finally, UBS Group cut shares of Smith & Nephew from a "buy" rating to a "neutral" rating in a research note on Wednesday, March 12th. Six research analysts have rated the stock with a hold rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $28.00.
Check Out Our Latest Stock Analysis on SNN
Smith & Nephew Price Performance
Shares of SNN stock traded up $0.75 during mid-day trading on Thursday, hitting $28.72. The company had a trading volume of 267,760 shares, compared to its average volume of 805,946. The company has a market capitalization of $12.58 billion, a P/E ratio of 13.29, a P/E/G ratio of 1.26 and a beta of 0.68. The stock's 50 day moving average price is $27.46 and its 200-day moving average price is $26.28. Smith & Nephew plc has a 52-week low of $23.69 and a 52-week high of $31.72. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11.
Smith & Nephew Increases Dividend
The firm also recently declared a semi-annual dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Friday, March 28th will be issued a $0.447 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a dividend yield of 2.5%. This is a positive change from Smith & Nephew's previous semi-annual dividend of $0.29. Smith & Nephew's payout ratio is currently 41.20%.
About Smith & Nephew
(
Free Report)
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.
Featured Stories
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
